UK utility weights for the EORTC QLU-C10D

被引:45
|
作者
Norman, Richard [1 ]
Mercieca-Bebber, Rebecca [2 ,3 ]
Rowen, Donna [4 ]
Brazier, John E. [4 ]
Cella, David [5 ]
Pickard, A. Simon [6 ]
Street, Deborah J. [7 ]
Viney, Rosalie [8 ]
Revicki, Dennis [2 ]
King, Madeleine T. [2 ]
机构
[1] Curtin Univ, Sch Publ Hlth, Perth, WA, Australia
[2] Univ Sydney, Fac Sci, Sch Psychol, Sydney, NSW, Australia
[3] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[4] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
[7] Univ Technol Sydney, Cl1ERE, Sydney, NSW, Australia
[8] Patient Ctr Res, Bethesda, MD USA
基金
英国医学研究理事会;
关键词
cancer; discrete choice experiment; health state valuation; utility; DISCRETE-CHOICE EXPERIMENT; PREFERENCE-BASED MEASURE; HEALTH STATES; INSTRUMENT; VALUATION; QLQ-C30; IMPACT; VALUES; QALYS;
D O I
10.1002/hec.3950
中图分类号
F [经济];
学科分类号
02 ;
摘要
The EORTC QLU-C10D is a new multi-attribute utility instrument derived from the widely used cancer-specific quality of life questionnaire, EORTC QLQ-C30. It contains 10 dimensions (physical functioning, role functioning, social functioning, emotional functioning, pain, fatigue, sleep, appetite, nausea, bowel problems), each with four levels. The aim of this study was to provide U.K. general population utility weights for the QLU-C10D. A U.K. online panel was quota-sampled to align the sample to the general population proportions of sex and age (>= 18 years). The online valuation survey included a discrete choice experiment (DCE). Each participant was asked to complete 16 choice-pairs, each comprising two QLU-C10D health states plus duration. DCE data were analysed using conditional logistic regression to generate utility weights. Data from 2,187 respondents who completed at least one choice set were included in the DCE analysis. The final U.K. QLU-C10D utility weights comprised decrements for each level of each health dimension. For nine of the 10 dimensions (all except appetite), the expected monotonic pattern was observed across levels: Utility decreased as severity increased. For the final model, consistent monotonicity was achieved by merging inconsistent adjacent levels for appetite. The largest utility decrements were associated with physical functioning and pain. The worst possible health state (the worst level of each dimension) is -0.083, which is considered slightly worse than being dead. The U.K.-specific utility weights will enable cost-utility analysis (CUA) for the economic evaluation of new oncology therapies and technologies in the United Kingdom, where CUA is commonly used to inform resource allocation.
引用
收藏
页码:1385 / 1401
页数:17
相关论文
共 50 条
  • [11] The EORTC QLU-C10D discrete choice experiment for cancer patients: a first step towards patient utility weights
    Gamper, Eva-Maria
    King, Madeleine T.
    Norman, Richard
    Loth, Fanny L. C.
    Holzner, Bernhard
    Kemmler, Georg
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2022, 6 (01)
  • [12] The EORTC QLU-C10D utility project - interim evaluation and comparison across countries
    Kemmler, Georg
    Gamper, Eva
    King, Madeleine T.
    Norman, Richard
    Nerich, Virginie
    Holzner, Bernhard
    QUALITY OF LIFE RESEARCH, 2017, 26 (01) : 32 - 33
  • [13] The EORTC QLU-C10D: the Hong Kong valuation study
    Xu, Richard Huan
    Wong, Eliza Lai-yi
    Luo, Nan
    Norman, Richard
    Lehmann, Jens
    Holzner, Bernhard
    King, Madeleine T.
    Kemmler, Georg
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2024, 25 (05): : 889 - 901
  • [14] Cancer-specific utility: clinical validation of the EORTC QLU-C10D in patients with glioblastoma
    Seyringer, Simone
    Pilz, Micha J.
    Bottomley, Andrew
    King, Madeleine T.
    Norman, Richard
    Gamper, Eva M.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2024,
  • [15] EORTC QLU-C10D value sets for Austria, Italy, and Poland
    E. M. Gamper
    M. T. King
    R. Norman
    F. Efficace
    F. Cottone
    B. Holzner
    G. Kemmler
    Quality of Life Research, 2020, 29 : 2485 - 2495
  • [16] EORTC QLU-C10D value sets for Austria, Italy, and Poland
    Gamper, E. M.
    King, M. T.
    Norman, R.
    Efficace, F.
    Cottone, F.
    Holzner, B.
    Kemmler, G.
    QUALITY OF LIFE RESEARCH, 2020, 29 (09) : 2485 - 2495
  • [17] German value sets for the EORTC QLU-C10D, a cancer-specific utility instrument based on the EORTC QLQ-C30
    Georg Kemmler
    Eva Gamper
    Virginie Nerich
    Richard Norman
    Rosalie Viney
    Bernhard Holzner
    Madeleine King
    Quality of Life Research, 2019, 28 : 3197 - 3211
  • [18] Comparison of PROPr and EORTC QLU-C10D in breast cancer and fibroadenoma patients
    Klapproth, Christoph Paul
    Fischer, Felix
    Rose, Matthias
    Hage, Anna Maria
    Margarete, Karsten Maria
    QUALITY OF LIFE RESEARCH, 2021, 30 (SUPPL 1) : S173 - S173
  • [19] Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30
    Madeleine T. King
    Rosalie Viney
    A. Simon Pickard
    Donna Rowen
    Neil K. Aaronson
    John E. Brazier
    David Cella
    Daniel S. J. Costa
    Peter M. Fayers
    Georg Kemmler
    Helen McTaggart-Cowen
    Rebecca Mercieca-Bebber
    Stuart Peacock
    Deborah J. Street
    Tracey A. Young
    Richard Norman
    PharmacoEconomics, 2018, 36 : 225 - 238
  • [20] Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30
    King, Madeleine T.
    Viney, Rosalie
    Pickard, A. Simon
    Rowen, Donna
    Aaronson, Neil K.
    Brazier, John E.
    Cella, David
    Costa, Daniel S. J.
    Fayers, Peter M.
    Kemmler, Georg
    McTaggart-Cowen, Helen
    Mercieca-Bebber, Rebecca
    Peacock, Stuart
    Street, Deborah J.
    Young, Tracey A.
    Norman, Richard
    PHARMACOECONOMICS, 2018, 36 (02) : 225 - 238